Curiously, the detection frequency of anti-Vpr IgG level was higher in the viremic patients of the tumor group (61.8% vs. 29.3%, P = 0.0017; Table 3) who had a lower CD4+ T-cell count (246 [121–404] vs. 409 [173–602], P = 0.0123; Table 3) and a lower CD4/CD8 ratio (0.322 [0.149–0.609] vs. 0.596 [0.286–1.062], P = 0.0021; Table 3). This evidence concerns the gene CD4 and neoplasm.